Please assess the completion status of the following clinical trial:

Trial Title: The Therapeutic Effect of Different Doses of Capecitabine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* According to the diagnostic criteria for colon cancer in the Consensus on Screening, Diagnosis and Treatment of Early Colorectal Cancer and Precancerous Lesions in China , colon cancer was confirmed by pathology~* TNM(tumor node metastasis) clinical stage was III or IV~* Predicted survival period \> 3 months~Exclusion Criteria:~* Patients with heart, liver, kidney and other important organ failure and contraindications to chemotherapy~* Patients who received other anti-tumor therapy before admission~* The disease progressed rapidly and could not be successfully completed by this researcher~* Allergic to related drugs

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- the control group: a total daily dose of 2,500 mg/m2 (Type: EXPERIMENTAL): The control group was treated with capecitabine at a conventional dose: 1,250 mg/m2 orally twice daily (once in the morning and once in the evening; equivalent to a total daily dose of 2,500 mg/m2). Treatment was given for 2 weeks, followed by a 1 week of discontinuation, with each cycle lasting 3 weeks, and there were a total of 4 cycles. Administration: Swallow the tablet whole with water 30 min after breakfast and dinner every day.
- the medium-dose group: a total daily dose of 2,000 mg/m2 (Type: ACTIVE_COMPARATOR): The medium-dose group was treated with medium-dose capecitabine: 1,000 mg/m2 orally twice daily (once in the morning and once in the evening; equivalent to a total daily dose of 2,000 mg/m2). Treatment was given for 2 weeks, followed by a 1 week of discontinuation, with each cycle lasting 3 weeks, and there were a total of 4 cycles. Administration: Swallow the tablet whole with water 30 min after breakfast and dinner every day.
- the low-dose group: a total daily dose of 1,500 mg/m2 (Type: ACTIVE_COMPARATOR): The low-dose group was treated with low-dose capecitabine: 750 mg/m2 orally twice daily (once in the morning and once in the evening; equivalent to a total daily dose of 1,500 mg/m2). Treatment was given for 3 weeks per cycle, with each cycle lasting 3 weeks, and there were a total of 4 cycles. Administration: Swallow the tablet whole with water 30 min after breakfast and dinner every day.

Based on this trial design, predict the completion outcome and termination type (if applicable).